



**Contact:**

Dr. Misha Plam

President & CEO

T: (303) 641-3669

[misha.plam@amidebio.com](mailto:misha.plam@amidebio.com)

[www.amidebio.com](http://www.amidebio.com)

## **Conrad Hummel, Ph.D. joins AmideBio as the Director of Business Development**

**BOULDER, CO, October 24, 2013** – AmideBio, LLC, a privately held biopharmaceutical company which has leveraged its novel processes for the manufacture of peptides and proteins to generate a pipeline of therapeutics including a novel Thermostable Insulin, announced today that Dr. Conrad Hummel has joined its Executive Management Team as the Director of Business Development.

Dr. Hummel brings over 20 years of experience in the pharmaceutical industry leading R&D and business development teams. Most recently he was at Array BioPharma where he was responsible for the outlicense of research stage therapies and the establishment of new research partnerships that took advantage of Array's discovery and CMC capabilities. Prior to this he built and directed Array's CMC and discovery chemistry external operations team and contributed to the discovery of clinical candidates in the fields of oncology, inflammation, and women's health.

Before Array, Dr. Hummel was a research scientist at Amgen and started his career as medicinal chemist at Glaxo in RTP, NC. He is the author of 14 peer-reviewed papers and one book chapter. He also is an inventor on a number of key therapeutic patents.

"We are very pleased to have Dr. Hummel join us as the Director of Business Development" says Dr. Misha Plam, President and CEO of AmideBio. "His experience with licensing and the establishment of research collaborations with leading biotech and pharmaceutical companies puts AmideBio in a strong position to find the best partners to advance and commercialize our technologies and pipeline assets."

"I am excited to be part of the AmideBio team," said Dr. Hummel. "Having both a strong technology base as they do with their BioPure™ process and a pipeline of therapeutics gives AmideBio multiple opportunities to bring value to pharmaceutical and biotech partners," he added.

Dr. Hummel received his undergraduate degree in chemistry from Gettysburg College in 1988. His graduate studies in the labs of Dr. K.C. Nicolaou took him through the University of Pennsylvania, The Scripps Research Institute, and culminated in a Ph.D. from the University of California, San Diego in 1993.

### **About AmideBio:**

AmideBio, based in Boulder, CO, is a biotechnology company founded on a unique process for the production of peptides and proteins, especially those that have been historically difficult to manufacture or produce in large quantities. The Company continues to expand its proprietary technology platform in the areas of protein production, biosimilar therapeutic manufacturing and internal research and development of novel biotherapeutics aimed at inflammatory and neurodegenerative diseases. The AmideBio BioPure™ process is providing the research community with some of the most pure peptide-derived products available to date, including amyloid-beta, an important protein believed to be involved with Alzheimer disease. The Company's platform offers an economical and environmentally sustainable process for large-scale production of Biosimilars, with the aim of providing patients with lower-cost medications. AmideBio's technology is the foundation for internal drug discovery and development against diseases such as Diabetes and Alzheimer's, where our BioPure™ materials have allowed for the discovery of novel targets as well as potential improvements in existing therapeutics.

- ENDS -